Vertex's CF Three-Drug Combo Excels In Phase III, But Filing Depends On Second Regimen's Results

Market analysts agreed across the board that Vertex Pharmaceuticals Inc. reported data at the upper end of what could be expected from a pair of Phase III trials evaluating a three-drug combination regimen for cystic fibrosis (CF) that includes experimental CFTR corrector VX-659. However, regulatory filings are on hold until the company also sees data from studies of a different triple combo using VX-445.

Vertex already is the market-leader in cystic fibrosis with Kalydeco (ivacaftor) and the two-drug combination regimens Orkambi (ivacaftor/lumacaftor) and Symdeko (ivacaftor/tezacaftor)